| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Corrado Angelini | Q37379259 |
| P2093 | author name string | Enrico Peterle | |
| P2860 | cites work | Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy | Q70603711 |
| Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy | Q71952881 | ||
| Dystrophin-positive fibers in Duchenne dystrophy: origin and correlation to clinical course | Q72020956 | ||
| Deflazacort in Duchenne dystrophy: study of long-term effect | Q72391527 | ||
| Effect of prednisone on protein metabolism in Duchenne dystrophy | Q72491853 | ||
| Vertebral fractures in boys with Duchenne muscular dystrophy | Q73511906 | ||
| Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies | Q74093649 | ||
| A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy | Q74199935 | ||
| Fracture risk in patients with muscular dystrophy and spinal muscular atrophy | Q74376696 | ||
| Quantitative MR evaluation of body composition in patients with Duchenne muscular dystrophy | Q78392555 | ||
| Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention | Q81244427 | ||
| MRI in the assessment of muscular pathology: a comparison between limb-girdle muscular dystrophies, hyaline body myopathies and myotonic dystrophies | Q83006075 | ||
| Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study | Q24616493 | ||
| SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy | Q24630041 | ||
| Systemic administration of PRO051 in Duchenne's muscular dystrophy | Q34172661 | ||
| Fracture prevalence in Duchenne muscular dystrophy | Q34990294 | ||
| The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy | Q36142376 | ||
| The role of corticosteroids in muscular dystrophy: a critical appraisal | Q36836822 | ||
| Deflazacort treatment of Duchenne muscular dystrophy | Q43517113 | ||
| Bone mineral density and fractures in boys with Duchenne muscular dystrophy | Q43850050 | ||
| Vertebral compression in Duchenne muscular dystrophy following deflazacort | Q43860541 | ||
| An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy | Q44121927 | ||
| High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. | Q44239685 | ||
| Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy | Q44359921 | ||
| Bone mineral density and bone metabolism in Duchenne muscular dystrophy | Q44536318 | ||
| Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro | Q44777123 | ||
| Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans | Q44897506 | ||
| Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. | Q45084815 | ||
| Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy | Q46377870 | ||
| Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. | Q53010051 | ||
| The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells | Q57043214 | ||
| Methylprednisolone selectively affects dystrophin expression in human muscle cultures | Q59558087 | ||
| Long-term benefit from prednisone therapy in Duchenne muscular dystrophy | Q67767537 | ||
| Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone | Q69265744 | ||
| Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit | Q69265751 | ||
| Prednisone in Duchenne muscular dystrophy | Q70028142 | ||
| Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study | Q70042821 | ||
| Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group | Q70134408 | ||
| Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group | Q70147605 | ||
| A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy | Q70166986 | ||
| Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) | Q70603707 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hormone | Q11364 |
| immunosuppressive drug | Q249619 | ||
| Duchenne muscular dystrophy | Q1648484 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 9-15 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Acta Myologica | Q15752538 |
| P1476 | title | Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy | |
| P478 | volume | 31 |
| Q89220022 | Current and Emerging Therapies for Duchenne Muscular Dystrophy |
| Q26741535 | Current and emerging treatment strategies for Duchenne muscular dystrophy |
| Q36025707 | D-Amino Acid Substitution of Peptide-Mediated NF-κB Suppression in mdx Mice Preserves Therapeutic Benefit in Skeletal Muscle, but Causes Kidney Toxicity |
| Q92621566 | Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? |
| Q38062690 | Fatigue in muscular dystrophies |
| Q35040061 | Gene expression profiling identifies molecular pathways associated with collagen VI deficiency and provides novel therapeutic targets |
| Q47324398 | Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles. |
| Q36334428 | Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients |
| Q38766431 | Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. |
| Q36171304 | Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. |
| Q53180281 | Molecular hydrogen alleviates motor deficits and muscle degeneration in mdx mice. |
| Q38302852 | Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy |
| Q33856905 | Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy |
| Q28072269 | Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture |
| Q28544012 | Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits |
| Q33809437 | Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy |
| Q92510845 | Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial |
| Q41052606 | Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital |
| Q57064365 | Taurine and Methylprednisolone Administration at Close Proximity to the Onset of Muscle Degeneration Is Ineffective at Attenuating Force Loss in the Hind-Limb of 28 Days Mice |
| Q35388411 | Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy |
Search more.